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HPV infection and carcinogenesis in the upper aero-digestive tract
ANDRÉS CASTILLO, BSC, PHD*
SUMMARY
Recently, molecular and epidemiological studies have shown an etiologic role for human papillomavirus (HPV) in a subset
of upper aero-digestive tract (UADT) cancers in women and men. Oral HPV infections acquired through oral sex seems to
be the main risk factor for HPV-associated oral cancers. The high-risk type HPV-16 was the most prevalent infection HPV-
positive in most oral cancers. Therefore, the prophylactic vaccine against HPV-16 could prevent HPV associated oral cancer
if the vaccine were demonstrated to be capable of preventing oral HPV-16 infection. Thus, these findings have created new
potential opportunities for the primary prevention of oral cancers.
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Infección por el VPH y la carcinogénesis en el tracto aero-digestivo superior
RESUMEN
Estudios moleculares y epidemiológicos han demostrado un papel etiológico del virus del papiloma humano (VPH) en
un subconjunto de cánceres de las vías aerodigestivas superiores (VADS) en mujeres y hombres. Las infecciones orales por
el VPH, adquiridas a través de sexo oral, parece ser el principal factor de riesgo para los cánceres orales asociados con este
virus. La infección con el tipo de alto riesgo del VPH-16 es el genotipo más prevalente de los genotipos del VPH encontrados
en la mayoría de los cánceres orales. Por lo tanto, la vacuna profiláctica en contra del VPH-16 podría ser útil para prevenir
el cáncer oral si la vacuna es capaz de prevenir la infección oral por VPH. Así, estos resultados han creado nuevas
oportunidades potenciales para la prevención primaria del cáncer oral.
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Infectious agents are suspected to play causal roles
in a variety of human malignancies. The public health
impact of the oncogenic effects of these infections is
considerable. Infection is estimated to be responsible
for about 17.8% of all incident cases of cancer world-
wide, accounting for 26.3% of all malignancies in
economically developing countries and 7.7% in
developed countries1.
The evaluation of causality for these infectious
agents as human carcinogens is difficult, given their
ubiquitous nature, the substantial length of time between
infection, and the cancer event, the nature of cofactors,
and the rarity of malignancy among those infected.
Thus, a central problem for the epidemiologist is to
define the natural history of infection and to identify
those factors that are related to the development of
cancer. Hence, informative biomarkers of the agent
(such as viral load), of the host (such as abnormal
antibody pattern), and of other oncogenic exposures
(such as tobacco use) are required to understand viral-
human interactions and develop interventions2.
Case-control studies have now recognized that human
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papillomavirus (HPV) infection in oral cavity is a
strong risk factor for head and neck squamous cell
carcinoma (HNSCC), and mostly for oropharyngeal
cancer. Risk is increased for high-risk HPV-16
infection3. Therefore, HPV infection in the oral cavity
has important health consequences, raising the need for
further studies about these aspects to clarify the
implications of an HPV diagnosis in oral cavity and
HNSCC.
Human Papillomavirus (HPV). HPVs are
nonenveloped icosahedral viruses with a diameter of 55
nm, belonging to the papillomaviridae family. This
epitheliotropic virus has 72 capsomers enclosing an 8
kbp-long circular DNA genome. Although its DNA is
double-stranded, only one strand contains open reading
frames (ORF) that are transcribed. The viral DNA has
eight ORFs and an upstream regulatory region, also
called the long control region (LCR), which contains an
origin of replication and cis-acting transcriptional
regulatory elements4. Figure 1 shows the genome
organization of HPV-16, the HPV type most strongly
related to cervical cancer. The early region of the HPV
genome contains six ORFs corresponding to E1, E2,
E4, E5, E6, and E7 genes, which encode proteins
necessary for viral replication and cell transformation.
The late region codes for the two proteins of the viral
capsid: L1, the major structural protein; and L2, the
protein linking to encapsulated DNA4.
Classification of papillomaviruses. The L1 ORF is
the most conserved gene in the papillomavirus (PV)
genome and has, therefore, been used to identify new
PV types over the past 15 years. A new PV isolate is
recognized as a new PV type if the complete genome
has been cloned and the DNA sequence of the L1 ORF
differs by more than 10% from any known PV types. A
difference between 2% and 10% homology defines a
subtype, and less than 2%, a variant5.
HPV has more than 100 types, of which approxi-
mately 90 have already been characterized and assigned
with numbers, and has five genuses: alpha-papillo-
mavirus, beta-papillomavirus, gamma-papillomavirus,
mu-papillomavirus, and nu-papillomavirus5. HPV is
also subdivided into two major groups, cutaneous and
mucosal, based on data from clinical manifestations6.
Most mucosal HPV types exist in the genital area,
which can be divided into high-risk and low-risk HPV
types7. High-risk HPV types increase the risk of cervi-
cal cancer, which is almost always associated with
HPV infection. To this date, approximately 20 HPV
types have been identified as high-risk. Among them,
HPV-16 and HPV-18 are considered to be associated
with 70% of all cervical cancer. In contrast, low-risk
HPV types, such as HPV-6 and HPV-11, cause genital
warts but not cancer.
Furthermore, HPVs have intratype variants.
However, information on variants is limited to certain
Figure 1. HPV-16 genomic organization. The early region of the HPV genome contains six ORFs
corresponding to E1, E2, E4, E5, E6, and E7 genes, which encode proteins necessary for viral replication
and cell transformation. The late region codes for the two proteins of the viral capsid: L1, the major
structural protein; and L2, the protein linking to encapsulated DNA.
235
Colombia Médica                          Vol. 42 Nº 2, 2011 (Abril-Junio)
HPV types. Yamada et al.8 showed five phylogenetic
clusters with distinct geographic distributions, analyzing
the sequences of E6, L1, and LCR of HPV-16 isolated
from cervical samples collected worldwide. The AA
(Asian American) variant was isolated mainly from
Central and South America and Spain. The African
variants 1 and 2 (Af1 and Af2) and Asian (As) variant
were present mainly from Africa and Southeast Asia,
respectively. In all regions other than Africa, European-
350T (E-350T) prototype, as well as European-350G
(E-350G) variant were detected.
The HPV life cycle and its carcinogenesis. The life
cycle of HPV is linked to the differentiation program of
the infected host cell, epidermal or mucosal epithelial
cell. Cells in the basal layer consist of stem cells, which
persist indefinitely, and a much larger number of «transit
amplifying cells», which arise from the stem cells and
divide a finite number of times until they become diffe-
rentiated, providing a reservoir of cells for subrabasal
regions9.
HPV initially infects the basal layer of epithelia via
minor abrasions. Viral entry into a cell is not clearly
understood. It is suspected that the heparin sulfate
mediates the initial attachment of virions to cells10 and
that HPV enters a cell via interaction with certain
receptors such as alfa-6 integrin for HPV-1611.
The first HPV genes to be expressed are E7 and E6
(Figure 2). The virus protein E7 promotes cell division
by binding to pRb, a tumor suppressor protein that
usually binds to and inactivates E2F, a transcription
factor. E2F released from pRb causes transcription of
genes involved in DNA replication and cell division. E6
Figure 2. The HPV life cycle. HPVs establish latent infection in the basal cells of the differentiating
epithelium as episomal multicopy circular nuclear plasmids to support the viral life cycle via action of the
viral replication proteins E1 and E2. Development of invasive cervical cancer is a stepwise process,
associated to integration of the high-risk HPV DNA into the host cell chromosome, up-regulating the
expression of viral oncoproteins E6 and E7.
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virus protein binds to and inhibits p53 protein, which is
active in repressing the cell cycle in the event of DNA
damage, and in triggering apoptosis in the case of
damage too severe to be repaired. E6 virus protein also
activates cellular telomerase that synthesizes the
telomere repeat sequences in eukaryotic cells and allows
their immortal replication12. The transforming activities
of high-risk HPV type represent a consequence of a
viral replication strategy that is driven by the necessity
to replicate the HPV genomes in suprabasal cells12.
During the early phases of infection, the copy number
of viral genome is between 50 and 100, and the viral
genome exists as extrachromosomal plasmid or episomal
form that replicates as the host cell chromosomes
replicate. As the infected cells differentiate, the rest of
the early viral genes, such as E1, E2, E4, and E5 genes,
become switched on13. E1 and E2 proteins, a helicase
and a transcription factor binding to LCR viral region,
respectively, support viral DNA replication so that the
infected stem cells can be maintained in the lesion for
a long period. E4 viral protein is thought to be involved
in activating the productive phase of the HPV life cycle.
E5, another viral protein, is involved in transformation,
enhancing the activity of EGF.
As infected daughter cells migrate to the upper
layers of the epithelium, viral L1 and L2 late gene
products, the major and minor viral capsid proteins, are
produced to initiate the vegetative phase of the HPV life
cycle, resulting in high-level amplification of the viral
genome. At the upper layers of stratified squamous
epithelia, viral DNA is packaged into capsids and
virions produced are freed through normal desquamation
processes, triggering little inflammation14. In addition,
E6 and E7 proteins inactivate interferon regulatory
factor15 so that HPV infection can remain persistent and
asymptomatic.
Infection with high-risk HPV is associated with
cervical dysplasia or cervical intraepithelial neoplasia
(CIN). Long-term, persistent HPV infection in these
lesions is thought to give rise to cervical cancers. CIN
I (mild dysplasia) and CIN II (moderate dysplasia)
lesions, in which the viral genomes replicate episomally,
show relatively low levels of E6 and E7 gene expression,
and are, in most cases, resolved spontaneously by an
effective immune response. In contrast, CIN III (severe
dysplasia, carcinoma in situ) and invasive cancer lesions,
where viral DNA is integrated into the host genome in
most cases, often display high-level expression of E6
and E7 genes16.
The integration of the viral genome into the host cell
is a very rare event with a predilection for host chromo-
somal fragile sites17, but after it has happened
carcinogenic transformation progresses rapidly. HPV
integration into the host genome induces the increased
E6 and E7 protein expressions since integration results
in disruption of HPV E2 gene, which is a negative
regulator of HPV E6 and E7 transcription. In addition,
once integrated, the E6 and E7 mRNA gains a longer
half-life by using host genome poly (A) signals.
However, the ultimate development of cervical cancer
is rarely accompanied by high expression of E6 and E7
proteins17.
High-risk HPV E6 and E7 oncoproteins can each
independently induce genomic instability in normal
human cells18. They cooperate to generate mitotic defects
and aneuploidy through the induction of centrosome
abnormalities in normal human epithelial cells, and the
characteristic multipolar mitoses in cervical lesions are
caused by centrosome abnormalities19. HPV onco-
proteins expressing cells also exhibit centrosome-
independent manifestations of genomic instability.
These manifestations include anaphase bridges that
may be caused by double-strand DNA breaks, as well as
lagging chromosomal material20. To date, information
on co-factors of HPV-related carcinogenesis in extra-
genital organs is quite limited. Muñoz et al.21 proposed
the following three groups of potential cofactors in
cervical carcinogenesis:
a. Environmental or exogenous cofactors, including
hormonal contraceptives, tobacco smoking, parity,
and co-infection with other sexually transmitted
agents;
b. Viral cofactors: such as HPV types, multiple HPV
type infections, HPV integration, HPV viral load,
and HPV variants; and
c. Host cofactors: including endogenous hormones,
genetic factors, and other factors related to the
immune response.
SQUAMOUS CELL CARCINOMAS (SCC) OF
THE UADT
Epidemiology. Oral cancer is the 11th most common
cancer in the world in terms of number of cases, while
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cancer of the pharynx ranks as 20th. Worldwide, about
389,000 new cases occurred in 2000, two-thirds of
which were in economically developing countries, and
these cancers are responsible for some 200,000 deaths
each year22. The male-female ratio of its incidence
varies from 2 to 15, depending on the anatomical sub-
site. An extremely high ratio is a characteristic of
cancers of the tongue, floor of mouth, and pharyngeal.
Cancers of the mouth and anterior two-thirds of the
tongue are predominant in economically developing
countries, whereas pharyngeal cancers are common in
developed countries and in Central and Eastern Europe.
In most countries, oral/pharyngeal cancer incidence
and mortality rates have either been stable or increasing
in the last four decades. Cancers of the esophagus are
the sixth most frequent cancers worldwide. In 2000, the
number of deaths due to esophageal cancer amounted to
some 337,500 out of a total of 6.2 million cancer deaths
worldwide. About 412,000 cases of cancer of the
esophagus occur each year, of which over 80% are in
economically developing countries23. The incidence of
esophageal cancer shows a distinct geographical
difference, which is more evident than for any other
types of cancer. In certain regions in Asia, the incidence
rates of ESCC are as high as 200 per every 100,000.
Even within these high-risk areas, there are striking
local variations in ESCC risk.
Genetic alterations. The genetic alterations observed
in the cancers of the UADT include activation of
protooncogenes such as cyclin D1, MYC, RAS, EGF
receptor, HST-1, and HST-2, as well as inactivation of
tumor suppressor genes (TSGs), such as those encoding
p53 and p16INK4a25. Likewise, in cancer of the
esophagus, the mutation of the p53 gene is detected in
35-70% of tumors, depending on geographic origin.
Mutations in p53 have also been observed in dysplasia
and in normal mucosa adjacent to cancer lesions, and
considered an early event. The p16INK4a gene is
another TSG that plays an important role in UADT
development, and p16INK4a is often subject to
hypermethylation of its promoter region, resulting in
down-regulation of its expression26.
Etiology. Consumption of tobacco and alcohol,
associated with low intake of fresh fruit, vegetables,
and meat, is causally associated with SCCs of the
UADT worldwide. However, the relative contribution
of these risk factors varies from one geographic area to
another27. Smoking is estimated to be responsible for
about 41% of oral/pharyngeal cancers in men, and 15%
in women worldwide. In more economically developed
countries, it is estimated that 90% of ESCCs are
attributable to tobacco and alcohol, with a multiplicative
increase in risk when individuals are exposed to both
factors. In addition, it has been reported that a genetic
polymorphism of aldehyde dehydrogenase 2 (ALDH2),
which plays a role in ethanol metabolism, is significantly
associated with ESCC in the Japanese population28.
Other environmental risk factors include nitro-
samines, deficiency of vitamins A and C, copper, and
zinc, poor nutrition, and ingestion of pickled and
preserved foods contaminated with fungi such as
Aspergillus flavum, Geotrichum candidum, and
Fusarium sp. Infectious agents, such as HPV and EBV,
have also been suggested to be involved in the develop-
ment of cancer of the UADT22.
HPV infection. The International Agency for
Research on Cancer considers that there is convincing
evidence that infection with HPV-16, -18, -31, -33, -35,
-39, -45, -51, -52, -56, -58, -59 and -66 can lead to
cervical  cancer30. Regarding HPV-16, evidence supports
its causal role in cancers of the vulva, vagina, penis, and
anus. The association of HPV with cancers of the
UADT is also suspected. The UADT consists of a
complex mucosa-covered conduit for food and air that
extends from the vermilion surface of the lips to the
esophagus. Major malignancies observed in the UADT
are cancers of the oral cavity, oropharynx, larynx, and
esophagus. Among them, HPV-16 is strongly suspected
to cause cancers of the oral cavity and oropharynx.
Limited evidence is available for the association of
HPV with cancers of the larynx and periungual skin, but
insufficient evidence for the roles of HPVs in cancer of
the esophagus30.
In our research group of the department of epide-
miology and preventive medicine at Kagoshima
University, Japan, we found HPV infections in 21
ESCC specimens (29%)31. Sequencing analysis of L1
region fragment identified HPV-16 genotype in six
Colombian cases (13%) and in five Chilean cases
(19%). Also, we found that a large proportion of ESCC
specimens harbor HPV-16 genotype in the integrated
form in a certain area with a high ESCC incidence in
China32.In studies on the association of HPV with
cancers of the oral cavity, oropharynx, and esophagus,
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using cancer specimens from Japan, Pakistan, and
Colombia, we found HPV DNA in around half of the
cases in SCCs of the oral cavity and oropharynx, and in
a smaller proportion of ESCCs; the high-risk type HPV-
16 was the most prevalent type; the viral load of HPV-
16 in SCC of the tonsil was similar to that of cervical
cancer and was higher than those of the other carcinomas
(> to one copy per cell); and HPV-16 genomes detected
in SCCs of the oral cavity, oropharynx, and esophagus
were frequently integrated in the host genome (Data in
publication process).
The most recent systematic review that included
5,046 SCC of head and neck cancers cases from 60
studies employing PCR-based methods showed that the
presence of HPV DNA was 25.9%, being significantly
higher in oropharyngeal SCC (35.6%; range 11%-
100%) than in oral (23.5%; range 4%-80%) or laryngeal
SCC (24.0%; range 0%-100%). HPV-16 accounted for
a larger majority of HPV-positive oropharyngeal SCC
(86.7%) than HPV-positive oral (68.2%) and laryngeal
SCC (69.2%)33. In another meta-analysis of 4,680
samples from 94 reports published during the period
between 1982 and 1997 showed that HPV was between
2 and 3 times more likely to be detected in precancerous
oral mucosa and 4.7 times more likely to be detected in
oral carcinoma than in normal mucosa34. Among the
studies used in their meta-analysis, the largest-scale
and best-designed study was the one by Maden et al.35
They examined 112 normal mucosa specimens and 118
oral carcinomas and detected HPV-16 in six cases of
oral carcinomas, but only one sample of normal muco-
sa. On the other hand, HPV-6 was detected in 12 and 10
oral carcinomas and normal mucosa, respectively. A
recent hospital-based case-control study of oro-
pharyngeal cancer in the US detected HPV-16 DNA in
72% of 100 paraffin-embedded tumor specimens, and
showed an association of oral HPV-16 infection with
oropharyngeal cancer. The study also showed that 64%
of patients with cancer were seropositive for the HPV-
16 oncoproteins E6 or E7, or both36. HPV DNA in situ
hybridization clearly showed its presence in the nuclei
of cancer cells and not in surrounding normal cells.
Another case-control study in the US found high-risk
HPV, mainly HPV-16, more frequently in exfoliated
oral cells from cancer patients than in those specimens
from controls, suggesting an association of oral HPV
infection with an increased risk of SCC in the head and
neck37. In addition, elevated antibodies against L1 and/
or E6/E7 were shown in an international study38.
 A review study also showed that 15.2% of the 2,020
esophageal SCC cases tested by PCR until 2002 were
HPV positive39. However, the role of HPV in esophageal
carcinomas remains unclear and controversial. European
prospective serologic studies that used stored serum
specimens40 as well as a Chinese case-control study41
found a strong association between the risk of ESCCs
and seropositivity to HPV-16. In contrast, other
retrospective studies conducted in Europe42 and a large
prospective serologic study in China43 found no
significant association of HPV-16 or HPV-18 with
SCCs or adenocarcinomas of the esophagus.
Recently, in the United States, Gillison44 showed
that HPV is a causal factor for a distinct group of UADT
cancers particularly in oropharyngeal cancers that occur
more frequently in men than women, where oral sex
appear to be the principal risk factor for HPV-associated
oral cancers in adolescents45. Also, the tumor HPV
status may be a strong and independent prognostic
factor for survival among patients with oropharyngeal
cancer46.
One important question is the route of HPV infection
in the oral cavity, oropharynx, and esophagus tract.
HPV is known to be sexually transmitted in the case of
the anogenital organs4. However, limited available data
suggest that HPV infection in oral cavity is possibly
sexually acquired: a history of sexually transmitted
diseases and number of oral sexual partners are
associated with both oral HPV infection47 and HPV-
positive oropharyngeal cancer36. Some data suggest
that the presence and persistence of an oral high-risk
HPV infection is associated with a persistent oral
infection in a spouse,48 as well as in an increased risk for
oral cancer among women with a history of cervical
cancer and their husbands49. In addition, other several
conceivable ways have been proposed for HPV infection
in oral and pharyngeal cavities. These include
intrapartum infection during the passage through the
infected birth canal, transplacental infection in uterus
prior to birth, and postnatal infection by contact. For
instance, HPV can be transmitted from a mother to her
newborn baby during vaginal delivery resulting in
recurrent respiratory papillomatosis. In addition, HPV
DNA has been detected in the foreskin of normal
newborn and in a high percentage of neonates vaginally
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delivered by HPV-infected mothers, as well as in the
amniotic fluid50.
Etiological role of HPV. Studies on prevalence of
HPV infections in premalignant and malignant lesions
of the oral cavity suggested the implication of HPV
during the early stages of oral neoplasia and a role in
malignant progression51. HPV-16 immortalized oral
keratinocytes have demonstrated to accumulate
progressive chromosomal aberrations52 and express
high levels of differentiation; however, there was no
tumorigenic activity in nude mice unless subjected to
chronic exposure to the tobacco carcinogen benzo(a)
pyrene53. Both benzo(a)pyrene stimulation and HPV-
16 infection of cultured oral epithelial cells have been
shown to confer anti-apoptotic characteristics, such as
down-regulation of Fas and Bax, as well as over-
expression of Bcl2 via p53 deregulation. Consequently,
HPV alone is not sufficient to induce malignant
transformation in several oral anatomic locations
compared to oropharyngeal cancer and tonsillar cancer
in particular. Futher studies are needed.
Methods for HPV detection. As HPVs cannot be
cultured easily; usually, HPV detection and genotype
assays are based on the detection of viral nucleic acids,
mostly viral DNA. HPV-DNA is detected by target
amplification methods and/or signal amplification
methods. The most used target amplification-based
method is polymerase chain reaction (PCR) using
conserved sequences of the HPV genome, almost
exclusively within the L1 open reading frame (ORF). In
our first studies in UADT by using formalin-fixed and
paraffin-embedded specimens31,32, we detected HPV-
DNA by GP5+/GP6+ primer pair for PCR54 that
amplified 150 base pair regions within L1, and the
results were confirmed by southern blot analysis. Also,
sequencing of L1 gene fragment amplified was used to
identify HPV genotype. In our subsequent studies in
UADT, using formalin-fixed and paraffin-embedded
specimens, we used an ultrasensitive short-fragment
PCR assay, the SPF10, which amplifies a 65-base-pair
region within L155. The HPV types were determined by
using the INNO-LiPA HPV genotyping v2 kit
(Innogenetics NV, Belgium), based on the reverse
hybridization principle. In brief, part of the L1 gene
region of the HPV genome is amplified by using SPF10
primers tagged with a biotin at the 52  and denatured.
Biotinylated amplicons are hybridized with specific
oligonucleotide probes immobilized on the strip. In
total, there were 25 genotypes (HPV-6, -11, -16, -18, -
31 -33, -35, -39, -40, -42, -43, -44, -45, -51, -52, -53, -
54, -56, -58, -59, -66, -68, -70, -73, and -74). Recently,
real-time PCR assays have been used to determine the
number of viral copies of HPV and to determine its
integration status56. HPV-16 physical status is
determined on the assumption that the E2 gene is
disrupted in integrated viral genome and, therefore, the
expected ratio of E2 to E6 copy numbers is zero. On the
other hand, the episomal viral genome has equivalent
copy numbers of the E2 and the E6 genes (an E2/E6
ratio is nearly equal to the unity) and mixed presence of
integrated and episomal form HPV-16 have an E2/E6
ratio between 0 and 1. Other target amplification-based
methods as reverse-transcriptase (RT-)PCR assays can
be applied to detect HPV mRNAs in fresh-frozen
specimens or samples in which RNA is well preserved
(i.e., liquid-based cytology samples of cervical
scrapings). Regarding signal amplification methods,
these are based on an initial hybridization step of
nucleic acids in the specimen with target-specific probes
in liquid phase or in situ on cells or tissue slides, after
which the signal (i.e., the hybridization event) is
amplified and ultimately visualized with one of the
various methodologies available. The liquid-phase
signal amplification method Digene Hybrid Capture 2
(HC2) assay57 (Qiagen, Gaithersburg, MD, USA) is the
first Food and Drug Administration (FDA) approved
test that screens for the presence or absence of oncogenic
HPV types. HC2 assay uses a mixture of RNA probes,
representing 13 HPV genotypes (HPV-16, -18, -31, -33,
-35, -39, -45, -51, -52, -56, -58, -59, and -68) to hybridize
to HPV-DNA positive samples. DNA–RNA hybrids
are subsequently captured in microplate wells coated
with antibodies that specifically recognize DNA–RNA
hybrids. For clinical validation strategy for candidate
HPV tests, we need a clinical equivalence analysis of
the candidate assay relative to a clinically validated
reference HPV test (HC2) by non-inferiority testing
using samples that originate from a population-based
screening cohort.
HPV vaccine. Preventive HPV vaccines are based
on empty virus-like particles (VLPs) assembled from
recombinant HPV coat proteins. Two HPV vaccines
are currently on the market: Gardasil and Cervarix. The
vaccine works by making the individual immune to two
240
Colombia Médica                  Vol. 42 Nº 2, 2011 (Abril-Junio)
key strains of the HPV (HPV-16 and -18). Together, the
two strains are known to cause approximately 70% of
all cervical cancer cases worldwide and some other
genital cancers. Gardasil58 also protects against the two
HPV types (HPV-6 and HPV-11) that cause 90% of
genital warts. In the UK, the Joint Committee on
Vaccination and Immunization recommended routine
vaccination for 11 to 12-year olds, including the
possibility of a catch-up campaign but only up to the age
of 16. Similar recommendations on vaccination of
young women against HPV to prevent cervical cancer
were made by Public Health officials in Australia,
Canada, Europe, and the United States59. It is suggested
that vaccinating most teenage girls could save hundreds
of lives a year, although, the benefits would not be seen
until those receiving the vaccine enter middle age.
Besides, Gardasil has been shown to prevent potential
precursors to anal, vulvar, vaginal, and penile cancers.
HPV vaccines are expected to protect against HPV
induced cancers of these areas, as well as HPV-induced
oral cancers. Also, laboratory research and clinical
trials have focused on the development of therapeutic
vaccines against HPV oncogenes, such as E6 and E7. It
is hoped that immune responses against the two
oncogenes might eradicate established tumors60.
CONCLUSIONS
The IARC estimated that 3% of oral cavity and 12%
of oropharynx cancers worldwide are attributable to
HPV1. Current generation HPV-16 and -18 L1 VLP
vaccines hold potential promise for the prevention of a
greater majority of HPV-positive cancers mainly HPV-
associated cervical cancer in female adolescents.
However, HPV vaccination in males may be a
particularly important approach to prevent UADT
cancer; most HPV-associated UADT cancers occur in
men. So, with the knowledge accumulated in recent
years on HPV-associated UADT cancers, there is reason
to be optimistic that HPV vaccines may be protective
against UADT HPV infection and, thus, be effective in
preventing HPV-associated UADT cancers in both
men and women. Hence, clinical trials to evaluate the
efficacy of vaccines in protecting against HPV and its
impact in HPV-associated UADT cancers are needed.
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